first_author,source_name,url,remarks,source_type,estimate_grade,country,state,city,study_inclusion_criteria,study_exclusion_criteria,sex,sampling_start_date,sampling_end_date,population_group,age,denominator_value,serum_pos_prevalence,seroprev_95_ci_lower,seroprev_95_ci_upper,sampling_method,test_name,test_manufacturer,test_type,isotypes,antibody_target,test_validation,sensitivity,specificity
Ahsan Ahmad,COVID-19 seroprevalence in Pakistan: a cross-sectional study,https://bmjopen.bmj.com/content/12/4/e055381.abstract,Better study available,Journal Article (Peer-Reviewed),National,Pakistan,"Punjab, Sindh, Baluchistan, Khyber Pakhtunkhwa, Azad Jammu & Kashmir, Gilgit Baltistan",NA,"This was a nationwide study in the four provinces (Punjab, Sindh, Baluchistan and Khyber Pakhtunkhwa) and two regions (Azad Jammu & Kashmir (AJK) and Gilgit Baltistan (GB)) of Pakistan. Individuals of all ages and genders were eligible to participate.","exclusion criteria: contraindications to venipuncture however, no such case was encountered",All,2020-10-21,2020-11-08,Household and community samples,Multiple groups,4998,0.0702,NA,NA,Stratified probability,Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit,Bioperfectus,LFIA,"['IgG', 'IgM']",NA,Validated by independent authors/third party/non-developers,NA,0.95
Derval Igoe,"Preliminary report of the results of the  Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A national seroprevalence study, June-July  2020",https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/scopi/SCOPI%20report%20preliminary%20results%20final%20version.pdf,Better study available,Institutional Report,National,Ireland,"Connaught, Leinster","Dublin, Sligo",People from 12 to 69 years of age were eligible to take part in the study. Participation was limited to this age group because of the practical difficulties of obtaining blood samples from children under 12 years of age and because people aged 70 years and above were advised to stay at home and not to undertake non-essential journeys at the time the study was being carried out.,NA,All,2020-06-22,2020-07-16,Household and community samples,Adults (18-64 years),1733,0.017,0.011,0.024,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Coronavirus Antibody Rapid Test","Abbott Laboratories,Fortress Diagnostics",CLIA,IgG,Nucleocapsid(N-protein),NA,NA,NA
Helen Ward,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,Better study available,Institutional Report,National,UK,England,NA,adult population 18 years and older in England registered with a General Practitioner in England,NA,All,2020-10-27,2020-11-10,Household and community samples,Multiple groups,161537,0.0556,0.0543,0.0571,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,IgG,Spike,Validated by independent authors/third party/non-developers,0.844,0.986
Helen Ward,"Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults.",https://dx.doi.org/10.1016/j.lanepe.2021.100098,Better study available,Journal Article (Peer-Reviewed),National,UK,England,NA,"We  included non-overlapping community samples from the adult population 18 years and older, using a self-administered questionnaire and LFIA test at home. Invitations were sent to named individuals randomly selected from the National Health Service (NHS) patient list which includes anyone registered with a General Practitioner (primary care physician) in England, covering almost the entire population.",NA,All,2020-06-20,2020-09-28,Household and community samples,Multiple groups,365104,0.0494,0.0485,0.0503,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,IgG,Spike,Validated by independent authors/third party/non-developers,0.844,0.986
Prajjval Singh,Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations,https://www.medrxiv.org/content/10.1101/2021.02.05.21251118v2,Better study available,Preprint,National,India,NA,NA,"healthy working individuals who have neither
been diagnosed with COVID-19, nor had been sick with any associated symptom in the
recent past. Our focus was to
screen people from urban vendor group who are relatively more exposed in society, e.g.
roadside workers, roadside fruit-vegetable sellers, rikshaw pullers, autorickshaw
drivers, milkmen, hawkers etc. With these stringent criteria, we screened unrelated
people who have not lived together.","we excluded those individuals in our survey whose family
members have ever been diagnosed with the COVID-19 in the past",All,2020-09-15,2020-12-15,Household and community samples,Adults (18-64 years),2301,0.3055,0.287,0.325,Simplified probability,Coviscreen kit total antibody (IgM+IgA+IgG),"Biosense Technologies, India",NA,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",NA,Validated by manufacturers,1,0.99
UK Biobank,UK Biobank SARS-CoV-2 Serology Study,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,Better study available,Institutional Report,National,UK,"England, Scotland, Wales",NA,NA,NA,All,2020-05-27,2020-12-04,Household and community samples,Multiple groups,18893,0.089927,NA,NA,Convenience,Not reported/ Unable to specify,NA,NA,NA,NA,NA,NA,NA
Wemimo Omiyale,Social determinants of ethnic disparities in SARS-CoV-2 infection: UK Biobank SARS-CoV-2 Serology Study,https://dx.doi.org/10.1136/jech-2023-220353,Better study available,Journal Article (Peer-Reviewed),National,UK,"England, Wales, Scotland.",NA,"The UK Biobank SARS-CoV-2 Serology Study is a longitudinal study of a subset of UK Biobank participants and their relatives (children or grandchildren >18 years).

In brief, UK Biobank is a prospective cohort study of 502 000 adults, recruited from the general population in England, Scotland and Wales between 2006 and 2010. Eligible participants were men and women aged 40–69 years, who were registered with the National Health Service (NHS) and living within approximately 25 miles of the 22 assessment centres; centres were distributed throughout the UK in settings to allow heterogeneity in socioeconomic, ethnic and urban-rural characteristics.

Between 7 May and 8 June 2020, all UK Biobank participants with a valid email address, resident in mainland UK and who had previously indicated willingness to be contacted about research activities were invited to join the Serology Study (see online supplemental figure S1).",excluding Northern Ireland,All,2020-05-15,2020-12-15,Household and community samples,Multiple groups,18887,0.0884,NA,NA,Stratified probability,Author designed (ELISA) -Spike,NA,ELISA,IgG,Spike,NA,NA,NA
Aaron Siegler,Us population-based survey of vaccine willingness and sars-cov- 2 antibody prevalence,https://www.croiconference.org/abstract/us-population-based-survey-of-vaccine-willingness-and-sars-cov-2-antibody-prevalence/,Conference paper,Presentation or Conference,National,US,NA,NA,address-based sample frame that includes nearly all residential addresses in the US.,NA,All,2020-08-09,2020-12-08,Household and community samples,Multiple groups,1454,0.0468,NA,NA,Simplified probability,Not reported/ Unable to specify,NA,NA,NA,NA,NA,NA,NA
Alexandra Rouquette,Comparison of Depression and Anxiety Following Self-reported COVID-19-Like Symptoms vs SARS-CoV-2 Seropositivity in France,https://dx.doi.org/10.1001/jamanetworkopen.2023.12892,Included,Journal Article (Peer-Reviewed),National,France,NA,NA,"On May 2, 2020, a letter was sent to a random sample of 371 000 people 15 years or older drawn from the national administrative and tax database (covering 96.4% of the population in France), with an intentional overrepresentation of individuals living in a household below the poverty level.","Individuals living in a residential care home for the elderly or in prison were excluded.

Of 85 074 individuals 15 years or older who completed the questionnaires at the 3 collection times, 28 568 were excluded because they did not return a blood sample for serologic testing, 1994 because of missing data on outcomes or exposures, and 9252 to respect the temporal sequence (exposure must precede the outcome).",All,2020-10-26,2020-12-14,Household and community samples,Multiple groups,45260,0.094,0.091,0.098,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,IgG,Spike,Validated by independent authors/third party/non-developers,0.864,0.962
Ana Basto-Abreu,Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico.,https://dx.doi.org/10.1038/s41467-022-28232-9,Included,Journal Article (Peer-Reviewed),National,Mexico,NA,NA,"10,216 households were selected. At
each household, an adult family member was asked to respond to a household
questionnaire and a questionnaire on the use of health services and health status of
each family member.",NA,All,2020-08-15,2020-11-15,Household and community samples,Multiple groups,9463,0.249,0.222,0.267,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9202,0.9952
Ana M. B. Menezes,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2.,https://dx.doi.org/10.1038/s41598-021-92775-y,Included,Journal Article (Peer-Reviewed),National,Brazil,NA,NA,Individuals living in the 133 sentinel cities of Brazil,"Previous diagnosis of COVID-19, those with missing information on symptoms, or those with symptoms.",All,2020-06-21,2020-06-24,Household and community samples,Multiple groups,31869,0.027,NA,NA,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,"['IgG', 'IgM']",NA,Validated by independent authors/third party/non-developers,0.848,0.9995
Beatriz Perez-Gomez,SARS-CoV-2 Infection During the First and Second Pandemic Waves in Spain: the ENE-COVID Study,https://dx.doi.org/10.2105/AJPH.2023.307233,Included,Journal Article (Peer-Reviewed),National,Spain,NA,NA,None listed - sounds like everyone sampled was eligible?,None listed,All,2020-04-27,2020-06-22,Household and community samples,Multiple groups,68287,0.06,0.057,0.064,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,IgG,Spike,Validated by independent authors/third party/non-developers,0.82,1
Bela Merkely,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",https://dx.doi.org/10.1007/s11357-020-00226-9,Included,Journal Article (Peer-Reviewed),National,Hungary,NA,NA,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",NA,All,2020-05-01,2020-05-16,Household and community samples,Multiple groups,10474,0.0068,0.005,0.0086,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,NA,NA
Cheikh Talla,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,Included,Journal Article (Peer-Reviewed),National,Senegal,NA,NA,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,All,2020-10-25,2020-11-26,Household and community samples,Multiple groups,1422,0.284,0.261,0.308,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,NA,NA
Cristina Royo Cebrecos,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",https://www.sciencedirect.com/science/article/pii/S266677622100096X,No representation,Journal Article (Peer-Reviewed),National,Andorra,NA,NA,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.",The only exclusion criterion was therefusal to provide the signed informed consent,All,2020-05-04,2020-05-28,Household and community samples,Multiple groups,72964,0.11,NA,NA,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,"['IgG', 'IgM']",NA,Validated by independent authors/third party/non-developers,0.92,1
Eric Vos,Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave,https://dx.doi.org/10.1136/jech-2020-215678,Included,Journal Article (Peer-Reviewed),National,Netherlands,NA,NA,Participants who had taken part in a large-scale nationwide serosurveillance study (PIENTER-3) in 2016/2017 from low vaccination coverage municipalities,NA,All,2020-03-31,2020-05-11,Household and community samples,Multiple groups,570,0.029,0.014,0.063,Stratified probability,Not reported/ Unable to specify,NA,ELISA,IgG,Spike,Validated by independent authors/third party/non-developers,0.844,0.99
Helen Ward,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,Included,Journal Article (Peer-Reviewed),National,UK,NA,NA,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",NA,All,2020-06-20,2020-07-13,Household and community samples,Multiple groups,99908,0.0596,0.0578,0.0614,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,IgG,Spike,Validated by independent authors/third party/non-developers,0.844,0.986
Laura Espenhain,"Prevalence of SARS-CoV-2 antibodies in Denmark: nationwide, population-based seroepidemiological study.",https://dx.doi.org/10.1007/s10654-021-00796-8,Included,Journal Article (Peer-Reviewed),National,Denmark,NA,NA,"For DSS-I, adults aged 18 years and older with an address in one of 30 municipalities which had a test facility (see below) at that time (n = 5), or were neighbouring a municipality with a test facility (n = 25) were eligible (approximately 45% of the population of Denmark). For DSS-II and DSS-III, people aged 12 years or older were selected by random sampling, with no restriction on municipality (n = 98). To make it a safe experience for children and motivate participation, parents living on the same address as invited children 12–17 years old, were also invited to have an antibody test. Parents’ antibody test results were not included in the seroprevalence calculation.",NA,All,2020-08-15,2020-09-30,Household and community samples,Multiple groups,11478,0.02,0.017,0.024,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,TotalAntibody,NA,Validated by independent authors/third party/non-developers,0.967,0.995
Luisa Castro,"Prevalence of SARS-CoV-2 Antibodies after First 6 Months of COVID-19 Pandemic, Portugal",https://wwwnc.cdc.gov/eid/article/27/11/21-0636_article,Included,Journal Article (Peer-Reviewed),National,Portugal,NA,NA,Resident of Portugal,NA,All,2020-09-08,2020-10-14,Household and community samples,Multiple groups,13398,0.022,0.02,0.025,Convenience,ADVIA Centaur Immunoassay System,Siemens,CLIA,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.981,0.999
Manoj V Murhekar,"SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey",https://dx.doi.org/10.1016/S2214-109X(20)30544-1,Included,Journal Article (Peer-Reviewed),National,India,NA,NA,We did a second household serosurvey among individuals aged 10 years or older in the same 700 villages or wards within 70 districts in India that were included in the first serosurvey.,Individuals aged younger than 10 years and households that did not respond at the time of survey were excluded.,All,2020-08-18,2020-09-20,Household and community samples,Multiple groups,29082,0.066,0.058,0.074,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1,0.996
Pablo Vial,"Seroprevalence, spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of Chile.",https://dx.doi.org/10.1186/s12879-022-07045-7,Included,Journal Article (Peer-Reviewed),National,Chile,"Coquimbo, Talca, Santiago",NA,"Residents (aged 7 years and older) of 3 urban areas in the center zone of Chile (Greater Santiago, Coquimbo-La Serena, Talca)",NA,All,2020-09-25,2020-11-25,Household and community samples,Multiple groups,2493,0.104,0.078,0.137,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),2019-nCoV IgG/IgM Antibody Detection Kit","Roche Diagnostics,Zhuhai Livzon Diagnostics Inc",Multiple Types,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,NA,NA
Patrick Sullivan,"Severe Acute Respiratory Syndrome Coronavirus 2 Cumulative Incidence, United States, August 2020–December 2020",https://dx.doi.org/10.1093/cid/ciab626,Included,Journal Article (Peer-Reviewed),National,US,NA,NA,household members aged >= 18 years old,NA,All,2020-08-09,2020-12-08,Household and community samples,Multiple groups,4654,0.0471,0.033,0.0611,Stratified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.98,0.993
Xuyang Tang,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,Included,Journal Article (Peer-Reviewed),National,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",NA,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,All,2020-05-01,2020-09-30,Household and community samples,Multiple groups,8967,0.019,NA,NA,Convenience,Author designed (ELISA) -Spike,NA,ELISA,IgG,Spike,Validated by developers,0.98,NA
Zhongjie Li,"Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China",https://dx.doi.org/10.1016/j.lanwpc.2021.100094,Included,Journal Article (Peer-Reviewed),National,China,NA,NA,Eligible participants were over one year old who lived in the surveyed areas for at least 14 days during the epidemic period (December 2019 to March 2020),NA,All,2020-04-10,2020-04-18,Household and community samples,Multiple groups,34857,0.0123,NA,NA,Stratified probability,"Finecare SARS-CoV-2 Antibody test,2019-nCoV IgG Rapid Test,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Author designed (Neutralization Assay)","Guangzhou Wondfo Biotech Co. Ltd,Innovita Biological Technology Co. Ltd,Bioscience Diagnostics,NA",Multiple Types,"['IgG', 'IgM', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,NA,NA
Government of Nepal,ENHANCED SURVEILLANCE ON SERO-PREVALENCE OF SARS-COV-2 IN GENERAL POPULATION,https://mohp.gov.np/attachments/article/708/First%20Sero-prevalence_final_report_04-04-2021.pdf,Institute report,Institutional Report,National,Nepal,NA,NA,The study population consisted of any person aged six (6) months or older and living in Nepal for a continuous period of at least 4 weeks prior to the first blood sampling date,"Exclusion criteria included refusal to give informed consent or contraindication to venepuncture. Additionally, to allow for enough time for exposure to infection and development of antibodies (IgM or IgG or other types), any person who had arrived in the country less than 4 weeks prior to the blood sample collection date was excluded.

The population under 6 months was excluded for operational difficulties in getting a blood sample and also because young infants have not been found to be significant source of COVID-19 infection.",All,2020-10-09,2020-10-22,Household and community samples,Multiple groups,3040,0.144,0.118,0.17,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,TotalAntibody,NA,Validated by independent authors/third party/non-developers,0.967,0.975
Instituto Nazionale di Statistica,FIRST RESULTS OF THE SEROPREVALENCE SURVEY ON SARS-CoV-2,https://www.istat.it/it/files//2020/08/ReportPrimiRisultatiIndagineSiero.pdf,Institute report,Institutional Report,National,Italy,"Abruzzo, Basilicata, Calabria, Campania, Emilia Romagna, Friuli-Venezia Giulia, Lazio, Liguria, Lombardy, Marche, Molise, Piemonte, Trentino-Alto Adige, Puglia, Sardegna, Sicily, Tuscany, Umbria, Valle D'Aosta, Veneto",NA,"The people selected were also asked to respond to a specific questionnaire  prepared by Istat, in agreement with the Technical Scientific Committee.",NA,All,2020-05-25,2020-07-15,Household and community samples,Multiple groups,64660,0.025,NA,NA,Stratified non-probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,IgG,NA,NA,NA,NA
KBS World,COVID-19 Serology Tests Still Show Low Antibody Rate of 0.07%,https://world.kbs.co.kr/service/news_view.htm?lang=e&Seq_Code=157801,Institute report,News and Media,National,Republic of Korea,NA,NA,The general population (not specified),NA,All,2020-08-15,2020-10-15,Household and community samples,Multiple groups,1379,0.0022,NA,NA,Unclear,Not reported/ Unable to specify,NA,NA,NA,NA,NA,NA,NA
Ministry of Health,ESTUDIO ENE-COVID: INFORME FINAL ESTUDIO NACIONAL DE SERO-EPIDEMIOLOGÍA DE LA INFECCIÓN POR SARS-COV-2 EN ESPAÑA,https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf,Institute report,Institutional Report,National,Spain,NA,NA,NA,NA,All,2020-06-08,2020-06-22,Household and community samples,Multiple groups,62167,0.052,0.049,0.055,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,IgG,NA,Validated by manufacturers,0.97,1
Ock Hyun-ju,0.03% of Koreans developed coronavirus antibodies: KCDC,https://www.google.com/url?rct=j&sa=t&url=http://www.koreaherald.com/view.php%3Fud%3D20200709000787&ct=ga&cd=CAAYEDIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNG8AlCeBcx2rR4FfgC726ll5TtgUw,Institute report,News and Media,National,Republic of Korea,Korea,NA,Participants of the National Nutrition Survey or individuals in a medical institution in Seoul,NA,All,2020-07-09,2020-07-09,Household and community samples,Multiple groups,3055,0.0003,NA,NA,Unclear,Not reported/ Unable to specify,NA,NA,NA,NA,NA,NA,NA
Puerto Rico Public Health Trust,Resultados Primera Fase Proyecto CASPER - Primer Estudio de Seroprevalencia de COVID-19 en Puerto Rico,https://sites.google.com/view/casperpr/análisis-y-resultados?authuser=0,Institute report,Institutional Report,National,Puerto Rico,NA,"Arecibo, Bayamón, Caguas, Fajardo,Mayagüez, Aguadilla, Metro / San Juan, Ponce","We conducted seven simultaneous CASPERs to collect representative data in each of the seven public health regions of Puerto Rico (Arecibo, Bayamon, Caguas, Fajardo, Mayagüez, Aguadilla, Metro / San Juan, Ponce).

A two-stage cluster sampling methodology was used to select a representative sample of households for interview and testing in each health region.","1,816 of 1,906 serum samples collected from 1,175 households were tested. In 76 samples the results were indeterminate and 14 specimens did not have enough volume to perform the test.",All,2020-11-20,2020-11-23,Household and community samples,Multiple groups,1816,0.028,NA,NA,Stratified probability,Not reported/ Unable to specify,NA,NA,"['IgG', 'IgM']",NA,NA,NA,NA
Secretaria de Salud,Secretaría de Salud presenta resultados preliminares de la Encuesta Nacional de Salud y Nutrición COVID-19,https://www.gob.mx/salud/prensa/255-secretaria-de-salud-presenta-resultados-preliminares-de-la-encuesta-nacional-de-salud-y-nutricion-covid-19?idiom=es,Institute report,News and Media,National,Mexico,NA,NA,Individuals in Mexico,NA,All,2020-08-15,2020-11-15,Household and community samples,Multiple groups,7098,0.25,NA,NA,Unclear,Not reported/ Unable to specify,NA,NA,NA,NA,NA,NA,NA
Sergei Kiselyov,1 in 7 Russians Have ‘Coronavirus Immunity’ – Official,https://www.themoscowtimes.com/2020/06/10/1-in-7-russians-have-coronavirus-immunity-official-a70540 ; https://www.interfax.ru/russia/712617,Institute report,News and Media,National,Russian Federation,NA,NA,People in 46 regions across Russia,NA,All,2020-06-10,2020-06-10,Household and community samples,Multiple groups,650000,0.14,NA,NA,Unclear,Not reported/ Unable to specify,NA,NA,NA,NA,NA,0.95,0.98
Statistics Jersey,SARS-CoV-2: Prevalence of antibodies in Jersey Community Survey - Round 3,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200707%20SJ.pdf,Institute report,Institutional Report,National,Jersey,NA,NA,All individuals aged 16 and over who formed part of the selected household were asked to participate in the survey.,"The survey did not perform testing on any person aged under 16 years and did not include residents of communal establishments (such as care homes).

The sample drawn excluded communal establishments (such as care homes), commercial properties and a small number of other properties known not to be residential in nature.",All,2020-06-21,2020-06-27,Household and community samples,Multiple groups,1386,0.04,0.028,0.052,Simplified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,"['IgG', 'IgM']",NA,Validated by manufacturers,0.9,0.9939
Arokiaswamy Velumani,SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,10.1101/2021.03.19.21253429,Better study available,Preprint,National,India,"Maharashtra, West Bengal, Tamil Nadu, Karnataka, Gujarat, Rajasthan, Bihar, Andhra Pradesh","Mumbia, Delhi, Kolkata, Chennai, Bangalore, Ahmedabad, Pune, Surat, Jaipur, Nagpur, Coimbatore, Visakhapatnam","We included 448,518 people of all ages who underwent testing for SARS-CoV-2 antibodies between June 12,
2020 and December 31, 2020 by Thyrocare Laboratories.12 Thyrocare conducts central laboratory testing in
Navi Mumbai from over 2200 franchised collection centers in all major cities in India. Thyrocare charges 600-
750 Rupees (US$8-10) for an antibody test.",NA,All,2020-06-12,2020-12-31,Household and community samples,Multiple groups,448518,0.31,NA,NA,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),NA,NA,NA
India com News Desk,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,News article,News and Media,National,India,NA,NA,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,NA,All,2020-06-28,2020-07-19,Household and community samples,Multiple groups,53000,0.15,NA,NA,Simplified probability,Not reported/ Unable to specify,NA,Multiple Types,NA,NA,NA,NA,NA
Joane Matta,Trust in sources of information on COVID-19 at the beginning of the pandemic's first wave and incident persistent symptoms in the population-based CONSTANCES cohort: A prospective study.,https://dx.doi.org/10.1016/j.jpsychores.2023.111326,News article,Journal Article (Peer-Reviewed),National,France,NA,NA,"The present study is a longitudinal analysis of data from the SAPRIS and SAPRIS-SERO surveys nested in the French CONSTANCES cohort.

The French CONSTANCES population-based cohort study received ethical approval and included approximately 200,000 volunteers aged 18–69 years at inclusion between 2012 and 2019.

Volunteers were selected among individuals covered by the general insurance scheme or partner health mutual societies (in all, 85% of the French population).","Based on Supplementary Fig. 1:

- 1589 did not respond;
- 2360 did not validate their questionnaire;
- 1032 with missing data on serology test results or self-reported COVID-19;
- 2780 excluded from the analysis because they answered “I don’t know” to the self-reported COVID-19 question;
- 1312 excluded from the analysis because of they indicated having had COVID-19 after the date of their serologic testing;
- 893 excluded from the analysis because they responded “I don’t know”, “I don’t want to answer”, or “other” to the questions about income or education;
- 2182 excluded from the analysis because they answered “I don’t know” on questions about trust in information sources on COVID-19;
- 2719 excluded from because of missing data on sex, education, income, self-rated health, or trust in information sources.

To reduce the risk of false-negative results, samples with indeterminate results (ie, optical density ratio ≥ 0.8 and < 1.1) were discarded.",All,2020-05-15,2020-11-15,Household and community samples,Multiple groups,20985,0.0419,NA,NA,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,IgG,Spike,Validated by manufacturers,0.87,0.975
Michael Bachner,Initial antibody tests indicate 200000  Israelis have had COVID-19 - report,https://www.google.com/url?rct=j&sa=t&url=https://www.timesofisrael.com/initial-antibody-tests-indicate-200000-israelis-have-had-covid-19-report/&ct=ga&cd=CAAYBjIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNHYeXqD2hIEiNnZoH5qLiVlZKxQjg,News article,News and Media,National,Israel,Israel,NA,"Those tested are a representative sample of the population in age, gender and place of residence, the Haaretz daily said in its report Tuesday.",NA,All,2020-06-01,2020-06-02,Household and community samples,Multiple groups,1700,0.025,NA,NA,Stratified probability,Not reported/ Unable to specify,NA,NA,IgG,NA,NA,NA,NA
Ambroise Ahouidi,Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal.,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702669/,No asymptomatics,Journal Article (Peer-Reviewed),National,Senegal,NA,"Dakar , Thiès, Ziguinchor, Saint-Louis, Kaolack, Kolda, Touba, Tambacounda, Louga, Bounkiling","The seroprevalence rate of SARS-CoV-2 IgG
was assessed in 10 cities in Senegal by testing plasma from volunteers attending healthcare clinics for reasons
unrelated to coronavirus disease 2019",NA,All,2020-06-15,2020-10-15,Household and community samples,Multiple groups,3231,0.204,NA,NA,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1,0.9963
Anna Solastie,"Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020-2022",https://dx.doi.org/10.1080/22221751.2023.2222849,No asymptomatics,Journal Article (Peer-Reviewed),National,Finland,"Helsinki and Uusimaa, Pirkanmaa, Northern Ostrobothnia, Northern Savonia , Southwest, Finland",NA,participate in the study in forty sequential random population surveys between April 2020 and December 2022.,Individuals living within institutional care and those previously invited to this study or the follow-up study of the serological population survey of the coronavirus epidemic [Citation15] were excluded.,All,2020-04-01,2020-06-30,Household and community samples,Multiple groups,3450,0.02,0.01,0.04,Simplified probability,Author designed (Multiplex),NA,NA,IgG,Nucleocapsid(N-protein),Validated by developers,0.928,1
Battogtokh Chimeddorj,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",https://dx.doi.org/10.1016/j.lanwpc.2023.100760,No asymptomatics,Journal Article (Peer-Reviewed),National,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratiﬁed multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2.",All,2020-10-13,2020-12-14,Household and community samples,Multiple groups,5000,0.015,0.012,0.02,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99
Camilo Zurita Salinas,Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Ecuadorian Population,https://www.researchgate.net/publication/344477310_SEROPREVALENCE_OF_ANTI-SARS-COV-2_IGG_ANTIBODIES_IN_ECUADORIAN_POPULATION,No asymptomatics,Journal Article (Peer-Reviewed),National,Ecuador,NA,Quito,"11,540 patients came to the laboratory to perform the antibody test in a clinical laboratory in Quito city. Written informed consent was signed by each patient",NA,All,2020-05-12,2020-07-20,Household and community samples,Multiple groups,11540,0.19,NA,NA,Self-referral,NovaLisa® SARS-CoV-2 IgG/IgM,NovaTec Immundiagnostics GmbH,ELISA,IgG,NA,NA,NA,NA
Daniel Gudbjartsson,Humoral Immune Response to SARS-CoV-2 in Iceland,http://dx.doi.org/10.1056/NEJMoa2026116,No asymptomatics,Journal Article (Peer-Reviewed),National,Iceland,NA,NA,"Sampled several groups - for seroprevalence, groups who had not been tested for PCR or tested negative PCR for coronavirus","Ran one analysis excluding COVID-19 confirmed, but inclusionary result also available",All,2020-04-27,2020-06-12,Household and community samples,Multiple groups,23452,0.003,NA,NA,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Wantai SARS-CoV-2 Total Ab ELISA","Roche Diagnostics,Beijing Wantai Biological",CLIA,"['IgA', 'IgG', 'IgM']",Spike,Validated by manufacturers,0.911,NA
Daniela Gornyk,SARS-CoV-2 Seroprevalence in Germany - A Population Based Sequential Study in Five Regions,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3834300,No asymptomatics,Preprint,National,Germany,NA,NA,"Individuals who received a written invitation, provided written informed consent and did not have contraindications for giving a blood sample were eligible for the study. All study materials were provided in German. Individuals with suspected or confirmed SARS-CoV-2 infections were not excluded. >=18 yrs

Individuals with suspected or confirmed SARS-CoV-2 infections were not excluded.",NA,All,2020-07-15,2020-12-15,Household and community samples,Multiple groups,13405,0.02,NA,NA,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,IgG,Spike,NA,NA,NA
Enyew Birru Tadesse,Seroprevalence and risk factors for SARS-CoV-2 Infection in selected urban areas in Ethiopia: a cross-sectional evaluation during July 2020,http://dx.doi.org/10.1016/j.ijid.2021.08.028,No asymptomatics,Journal Article (Peer-Reviewed),National,Ethiopia,NA,NA,"In Ethiopia, each town is divided into enumeration areas (EAs) with clear geographic demarcation. Each EA has on average 200 households. 219 EAs (76 EAs in Addis Ababa and 143 EAs in other towns) were selected randomly. All households within the chosen EAs were listed and then 40 households were randomly selected. All individuals ≥15 years of age in the randomly selected households were eligible to participate.",NA,All,2020-06-24,2020-07-08,Household and community samples,Multiple groups,16932,0.035,0.032,0.038,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,IgG,Nucleocapsid(N-protein),Validated by developers,0.545,1
Hannelore Neuhauser,Germany's low SARS-CoV-2 seroprevalence confirms effective containment in 2020: Results of the nationwide RKI-SOEP study,https://www.nature.com/articles/s41598-022-23821-6,No asymptomatics,Journal Article (Peer-Reviewed),National,Germany,NA,NA,German residents who are a part of the nationwide RKI-SOEP study.,NA,All,2020-10-15,2020-11-15,Household and community samples,Multiple groups,14781,0.013,0.009,0.017,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,IgG,Spike,Validated by independent authors/third party/non-developers,0.811,0.997
Hossein Poustchi,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,No asymptomatics,Journal Article (Peer-Reviewed),National,Iran,NA,"Ahvaz, Ardabil, Babol , Esfahan , Gorgan, Hamedan, Kerman, Kermanshah, Mashhad, Qom, Rasht, Sanandaj, Sari, Shiraz, Tabriz, Tehran, Urmia, Zahedan","We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,All,2020-04-17,2020-06-02,Household and community samples,Multiple groups,3530,0.171,0.146,0.195,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.982
Josiane Warszawski,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort â€“ EPICOV,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,No asymptomatics,Preprint,National,France,NA,NA,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,All,2020-05-01,2020-05-31,Household and community samples,Multiple groups,12114,0.045,0.04,0.051,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,IgG,Spike,Validated by manufacturers,0.944,NA
Josiane Warszawski,Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort.,https://dx.doi.org/10.1186/s12879-021-06973-0,No asymptomatics,Journal Article (Peer-Reviewed),National,France,NA,NA,"""Individuals  aged  15  years  or  older  living  in  mainland  France or three of the five French overseas territories were randomly  selected  from  the  FIDELI  administrative  sampling  frame.""",NA,All,2020-05-02,2020-06-02,Household and community samples,Multiple groups,12114,0.045,0.039,0.05,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,IgG,Spike,NA,0.944,1
Karampreet Sachathep,"Seroprevalence of SARS-CoV-2 in 10 Regional Capitals of Cameroon, October-December 2020",10.22541/au.168319263.36814253/v1,No asymptomatics,Preprint,National,Cameroon,NA,NA,">5, from community sites in each regional capital","""Children < 5 years were excluded due to the difficulty in obtaining blood from young children, especially in such public settings.""",All,2020-10-16,2020-12-15,Household and community samples,Multiple groups,9332,0.105,0.091,0.12,Convenience,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","Abbott Laboratories,Beijing Wantai Biological",Multiple Types,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",NA,NA,NA
Kastytis Smigelskas,SARS-CoV-2 Seroprevalence in Lithuania: Results of National Population Survey,https://www.journals.vu.lt/AML/article/view/22344,No asymptomatics,Journal Article (Peer-Reviewed),National,Lithuania,"Vilnius County, Kaunas county, Klaipėda County, Tauragė County, Utena county
","Vilnius, Kaunas, Klaipėda
",Randomly selected adult participants (18 years and older) were asked by mail to visit a designated health care unit to undergo the SARS-CoV-2 antibodies test and fill in the questionnaire.,NA,All,2020-08-10,2020-09-10,Household and community samples,Multiple groups,3089,0.014,0.0092,0.0199,Simplified probability,AMP Rapid Test SARS-CoV-2 IgG/IgM,AMEDA Labordiagnostik GmbH,LFIA,"['IgG', 'IgM']",NA,Validated by independent authors/third party/non-developers,0.92,0.994
Kazem Khalagi,Prevalence of COVID-19 in Iran: results of the first survey of the Iranian COVID-19 Serological Surveillance programme,http://dx.doi.org/10.1016/j.cmi.2021.06.002,No asymptomatics,Journal Article (Peer-Reviewed),National,Iran,NA,NA,"People with a unique Iranian national identification number registered in the primary health-care electronic health record systems (PHC-EHRS) (SIB, SINA and NAB), who were 6 years of age or older and had sufficient physical ability to attend blood sampling centers were included.",Individuals who had contraindications for venous blood sampling were excluded.,All,2020-08-03,2020-10-31,Household and community samples,Multiple groups,11256,0.142,0.133,0.152,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,IgG,NA,Validated by independent authors/third party/non-developers,0.74,0.98
Lloyd B Mulenga,"Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey",https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00053-X/fulltext,No asymptomatics,Journal Article (Peer-Reviewed),National,Zambia,"Kabwe, Livingstone, Lusaka, Nakonde, Ndola, Solwezi",NA,"Residents of households in six districts of Zambia (Kabwe, Livingstone, Lusaka, Nakonde, Ndola, and Solwezi) between July 4 and July 27, 2020. All individuals (of any age) who had slept in the selected house the night before the survey was done were eligible for participation in the survey.",excluding 333 participants for whom epidemiological data were disassociated from laboratory results,All,2020-07-04,2020-07-27,Household and community samples,Multiple groups,2704,0.021,0.011,0.031,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,IgG,Spike,NA,NA,NA
Lujain Alassaf,Community-Based Seroprevelance of SARS-CoV-2 in Saudi Arabia,https://dx.doi.org/10.7759/cureus.32419,No asymptomatics,Journal Article (Peer-Reviewed),National,Saudi Arabia,"Asir, Albaha, Najran, Jazan, Eastern Province, Makkah, Madinah",NA,"""The study was conducted in seven regions in Saudi Arabia: Asir, Albaha, Najran, Jazan, Eastern Province, Makkah, and Madinah regions. All districts from the selected regions were included.""

""Inclusion criteria included all individuals living in the same residential area (for the last six months) in the selected seven regions in Saudi Arabia, prior positive PCR result for COVID-19 and symptoms free for greater than or equal to 14 days, and never tested for COVID-19 and asymptomatic.""","""Those previously labeled as positive COVID-19 cases (in less than 14 days) were excluded.""",All,2020-07-15,2020-10-15,Household and community samples,Multiple groups,14118,0.191,NA,NA,Stratified non-probability,Colloidal Gold IgM/IgG rapid assay kit,BGI Genomics,ELISA,"IgG, IgM",[],Validated by manufacturers,0.99,NA
Manoj Murhekar,"Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020",http://dx.doi.org/10.4103/ijmr.IJMR_3290_20,No asymptomatics,Journal Article (Peer-Reviewed),National,India,NA,NA,General population - individuals aged 18 yr or more in selected representative 736 districts in India,NA,All,2020-05-11,2020-06-04,Household and community samples,Multiple groups,28000,0.0073,0.0034,0.0113,Stratified probability,"Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Anti-SARS-CoV-2 ELISA IgG","Zydus Diagnostics,EUROIMMUN",ELISA,IgG,"['Spike', 'Whole-virusantigen']",NA,NA,NA
Marcela Mercado-Reye,"Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study.",https://dx.doi.org/10.1016/j.lana.2022.100195,No asymptomatics,Journal Article (Peer-Reviewed),National,Colombia,NA,"Bogota, Medellin, Cali, Barranquilla, Cucuta,
Bucaramanga and Villavicencio Leticia, Ipiales and Guapi","Seven of the ten most populated cities in Colombia (Bogot a, Medell ın, Cali, Barranquilla, Cucuta, Bucaramanga and Villavicencio) as well as cities in key border regions (Leticia, Ipiales and Guapi) were involved. Individuals in the selected households were invited to participate.",NA,All,2020-09-21,2020-12-11,Household and community samples,Multiple groups,17863,0.3253,0.32,0.33,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.86,0.99
Mario Poljak,"Seroprevalence of SARS-CoV-2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned",https://dx.doi.org/10.1016/j.cmi.2021.03.009,No asymptomatics,Journal Article (Peer-Reviewed),National,Slovenia,NA,NA,"probability-based sample of the Slovenian population comprising data from 2.1 million people was selected from the Central Population Register (n = 3000). 
All participants provided written informed consent before enrolment and for individuals younger than 18 years a parent or legal guardian provided consent",NA,All,2020-04-20,2020-05-01,Household and community samples,Multiple groups,1316,0.0087,0.004,0.0138,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,NA,NA
Massimo Ralli,SARS-CoV-2 seroprevalence in the Vatican City State,https://dx.doi.org/10.1016/j.ejim.2021.01.029,No asymptomatics,Journal Article (Peer-Reviewed),National,Holy See,Vatican City State,Vatican City,"residents and employees of the Vatican City State,
regardless of symptoms or contacts with positive cases",repeated tests over time on the same subject were not included,All,2020-09-01,2020-09-30,Household and community samples,Multiple groups,514,0.0311,NA,NA,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,TotalAntibody,Spike,Validated by manufacturers,0.9748,0.998
Mayte Perez-Olmeda,Evolution of antibodies against SARS-CoV-2 over seven months: Experience of the nationwide seroprevalence ENE-COVID study in Spain.,https://www.sciencedirect.com/science/article/pii/S138665322200066X,No asymptomatics,Journal Article (Peer-Reviewed),National,Spain,NA,NA,Samples from all participants in the ENE-COVID study who agreed to donate a blood sample (ENE-COVID is a nationwide population-based longitudinal seroepidemiologic study in Spain),NA,All,2020-11-16,2020-11-29,Household and community samples,Multiple groups,5827,0.054,0.048,0.06,Simplified probability,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,IgG,Spike,Validated by independent authors/third party/non-developers,0.988,1
Melanie Deschasaux-Tanguy,ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study.,https://dx.doi.org/10.1038/s41598-023-30714-9,No asymptomatics,Journal Article (Peer-Reviewed),National,France,NA,NA,"""In May 2020, participants from the Constances, E3N-E4N and NutriNet-Santé cohort studies answering SAPRIS questionnaires were also invited to take part in the SAPRIS-SERO project which aimed to estimate the seroprevalence of antibodies against SARS-CoV-2 at the population level, as previously described12,13.""

From https://doi.org/10.1186%2Fs12879-021-05864-8:
""SAPRIS is based on a consortia of prospective cohort studies involving ... three general population-based adult cohorts:

- 1) CONSTANCES, a “general population” cohort including 204,973 adults aged 18 to 69 at inclusion and randomly selected from 2012 to be a representative sample of the French adult population affiliated to the General Health Insurance Fund (the source population, that is, approximately 85% of the total French population) [8]. Among CONSTANCES participants, 66,881 are followed by internet, the rest through mailed questionnaires.

- 2) E3N / E4N, a multigenerational adult cohort based on a community of families with 113,000 participants (including women recruited in 1990 and still actively followed-up, their offspring and the fathers of these offspring) among whom 89,606 followed by internet, the rest through mailed questionnaires [9].

- 3) NutriNet-Santé, a nutritional general population-based internet cohort started in 2009, with 170,000 included participants among whom 151,122 were still followed-up in 2020 [10].""",NA,All,2020-05-15,2020-11-15,Household and community samples,Multiple groups,67340,0.0101,NA,NA,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG),Author designed (Neutralization Assay)","EUROIMMUN,NA","ELISA,ELISA,Neutralization Assay","['IgG', 'Neutralizing']","['Nucleocapsid (N-protein)', 'Spike']",NA,NA,NA
Mohsina Haq,SARS-CoV-2: big seroprevalence data from Pakistan-is herd immunity at hand?.,https://dx.doi.org/10.1007/s15010-021-01629-2,No asymptomatics,Journal Article (Peer-Reviewed),National,Pakistan,NA,NA,Residents in Pakistan,NA,All,2020-07-15,2020-07-31,Household and community samples,Multiple groups,15390,0.424,0.415,0.4314,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.988,1
Robert Paulino Ramirez,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,https://dx.doi.org/10.4269/ajtmh.20-0907,No asymptomatics,Journal Article (Peer-Reviewed),National,Dominican Republic,NA,NA,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,NA,All,2020-04-15,2020-06-15,Household and community samples,Multiple groups,12897,0.055,NA,NA,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,IgG,Spike,Validated by independent authors/third party/non-developers,0.567,1
Sayed Ataullah Saeedzai,"Prevalence of COVID-19 and its Related Deaths in Afghanistan: A Nationwide, Population-Based Seroepidemiological Study July 202",https://moph.gov.af/sites/default/files/2020-08/Final%20COVID-19%20Survey%20English%20Report.pdf,No asymptomatics,Journal Article (Peer-Reviewed),National,Afghanistan,NA,NA,"Blood samples are collected from two household member randomly (one from 5 to 17 years
and another from equal and above 18 years of age)","Due to shortage of time and to have valid
data, insecure and inaccessible Enumerated Areas are not included in the study.",All,2020-06-01,2020-06-15,Household and community samples,Multiple groups,9514,0.315,NA,NA,Stratified probability,Not reported/ Unable to specify,NA,LFIA,"['IgG', 'IgM']",NA,Validated by manufacturers,NA,NA
Shay Reicher,Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel,https://dx.doi.org/10.1007/s10654-021-00749-1,No asymptomatics,Journal Article (Peer-Reviewed),National,Israel,NA,NA,The study population included insured individuals who arrived at the HMOs to undergo a blood test for any reason.,"Excluding participants with missing age and/or sex data, invalid test results",All,2020-06-28,2020-09-14,Household and community samples,Multiple groups,54357,0.046,0.044,0.048,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",ELISA,IgG,Spike,Multiple tests with diff validations or values derived from each type,NA,NA
Siaw Boon,Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.,https://dx.doi.org/10.1001/jamanetworkopen.2021.32923,No asymptomatics,Journal Article (Peer-Reviewed),National,China,NA,NA,"Adults 18 years or older were invited through various public channels, including posters, e-mails, and social media.",Individuals with COVID-19 confirmed in Hong Kong or elsewhere were excluded.,All,2020-09-29,2020-11-23,Household and community samples,Multiple groups,1046,0.001,NA,NA,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Author designed (ELISA) -Spike","Roche Diagnostics,NA",Multiple Types,"['IgG', 'Notreported']",Spike,Multiple tests with diff validations or values derived from each type,NA,NA
Siriphone Virachith,"Low seroprevalence of COVID-19 in Lao PDR, late 2020",https://dx.doi.org/10.1016/j.lanwpc.2021.100197,No asymptomatics,Journal Article (Peer-Reviewed),National,Lao People's Democratic Republic,"Vientiane Prefecture, Oudomxay, Luangprabang, Savannakhet, Champassak",NA,"all inhabitants aged five and above were invited to participate (from 5 provinces: Vientiane Capital, two provinces in the North-Luang-Prabang, Oudomxay and two provinces in the South -Savanakhet and Champassak). If a designated village could not be reached due to obstacles such as inaccessibility during the rainy season, the nearest village accessible was selected as an alternative",NA,All,2020-08-12,2020-09-25,Household and community samples,Multiple groups,2433,0.052,0.042,0.065,Stratified probability,Author designed (ELISA) - Nucleocapsid,NA,ELISA,NA,Nucleocapsid(N-protein),NA,NA,NA
Statistik Austria,COVID-19 Prävalenz und Seroprävalenz,http://www.statistik.at/wcm/idc/idcplg?IdcService=GET_PDF_FILE&dDocName=124957,No asymptomatics,Institutional Report,National,Austria,NA,NA,Individuals aged 16 and over in private households in Austria,NA,All,2020-11-12,2020-11-14,Household and community samples,Multiple groups,2229,0.047,0.038,0.056,Simplified probability,Author designed (Neutralization Assay),NA,Multiple Types,NA,NA,NA,NA,NA
Stefano Tancredi,Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study.,https://dx.doi.org/10.1007/s15010-023-02011-0,No asymptomatics,Journal Article (Peer-Reviewed),National,Switzerland,"Basel-Landschaft, Basel-Stadt, Bern, Fribourg, Grisons, Lucerne, Neuchâtel, Saint Gallen, Ticino, Vaud, Zurich",NA,"""This study is part of Corona Immunitas [16]. Repeated population-based serological studies were conducted in different regions of Switzerland.""

""We included 13,291 participants (in period 1 n = 3402, in period 2 n = 5611, and in period 3 n = 4278) aged 20 and older from 11 Swiss cantons (Additional file1: Fig. S1).""","Based on Figure S2:
- participants under 20 years of age;
- participants with missing serology data.
""For the second objective of this study, we excluded participants who completed the questionnaire more than 30 days before or after having provided the blood sample for the serology test. The reason for this exclusion was to avoid a possible mismatch between serology results and information reported in the questionnaires (preventive behaviours, health status and socioeconomic status). For the same reason, we also excluded participants who provided information on vaccination status more than 11 days before or after providing the blood sample for the serology test.""",All,2020-05-01,2020-10-31,Household and community samples,Multiple groups,3402,0.037,0.021,0.049,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS),Swiss Federal Institute of Technology,"other, CLIA",IgG,Spike,Validated by developers,0.966,0.997
Takashi Yoshiyama,"Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020",https://dx.doi.org/10.3201/eid2702.204088,No asymptomatics,Journal Article (Peer-Reviewed),National,Japan,NA,"Tokyo, Osaka, Miyagi","We conducted a seroprevalence survey of SARS- CoV-2 infection in 3 prefectures of Japan: Tokyo, Osaka, and Miyagi. Eligible participants were persons >20 years of age living in Japan.",The Tokyo and Miyagi prefectures excluded otherwise eligible participants with temperatures ≥37.5°C.,All,2020-06-01,2020-06-07,Household and community samples,Multiple groups,7950,0.001,0.0004,0.002,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Roche Diagnostics,Abbott Laboratories",CLIA,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by manufacturers,NA,NA
Tatjana Vilibic-Cavlek,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,https://dx.doi.org/10.3390/pathogens10060774,No asymptomatics,Journal Article (Peer-Reviewed),National,Croatia,NA,NA,NA,NA,All,2020-05-15,2020-07-15,Multiple general populations,Multiple groups,1088,0.022,0.014,0.033,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",NA,NA,NA
Taufiqur Bhuiyan,Seroprevalence of SARS-CoV-2 antibodies in Bangladesh related to novel coronavirus infection,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809641/,No asymptomatics,Journal Article (Peer-Reviewed),National,Bangladesh,NA,NA,general population from urban and slum areas of Dhaka and outside of Dhaka,NA,All,2020-04-15,2020-10-15,Household and community samples,Multiple groups,2582,0.304,0.24,0.37,Simplified probability,Author designed (ELISA) -Spike,NA,ELISA,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1,0.98
Xin Xu,Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China,https://www.nature.com/articles/s41591-020-0949-6,No asymptomatics,Journal Article (Peer-Reviewed),National,China,"Hubei, Sichuan, Guangdong","Wuhan, Guangzhou, Chengdu","We enrolled individuals from different
populations in seven cities in Huibei Province (Wuhan, Honghu and Jingzhou),
Guangdong Province (Guangzhou and Foshan), Sichuan Province (Chengdu) and
Chongqing in China. A total of 17,368 individuals, including 2,535 patients, 4,384
healthcare workers, 219 family members of healthcare workers, 346 staff members
from hotels designated for accommodation of healthcare workers responsible for
COVID-19 management, 442 factory workers and 9,442 community residents,
were enrolled. Healthcare workers, family members, outpatients and community
residents were recruited by voluntary participation by a public call. Patients
undergoing hemodialysis, hotel staff members and factory workers were required
to take the serological test at the participant centers after implementation of
regulations for COVID-19 surveillance of these populations during the epidemic
in China.",NA,All,2020-03-09,2020-04-10,Multiple populations,Adults (18-64 years),10449,0.008,NA,NA,Self-referral,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,NA,0.993
Clemens Fuest,Die Deutschen und Corona Schlussbericht der BMG-„Corona-BUND-Studie“,https://www.ifo.de/en/publikationen/2020/monograph-authorship/die-deutschen-und-corona,No english,Institutional Report,National,Germany,NA,NA,NA,NA,All,2020-10-26,2020-11-18,Household and community samples,Multiple groups,9929,0.011,0.0092,0.0133,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,NA,0.998
Mario Rene Mejia Nunez,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,No english,Journal Article (Peer-Reviewed),National,Honduras,NA,NA,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",All,2020-06-16,2020-06-23,Household and community samples,Multiple groups,792,0.062,NA,NA,Stratified probability,Not reported/ Unable to specify,NA,LFIA,"['IgG', 'IgM']",NA,Validated by manufacturers,0.934,0.977
Denis Nash,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",https://dx.doi.org/10.1093/cid/ciac423,No phi_c,Journal Article (Peer-Reviewed),National,US,All 50 US states; the District of Columbia; Puerto Rico; Guam.,NA,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",NA,All,2020-05-15,2020-09-15,Household and community samples,Multiple groups,4232,0.022,0.017,0.028,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988
Lara Ferrero Gomez,Sero-Epidemiological Survey and Profile of SARS-CoV-2 Infection in Cape Verde,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3762489,No phi_c,Preprint,National,Cabo Verde,NA,NA,"As an inclusion criterion, individuals aged 10 to 80 years (including extremes) and residing in Cape Verde were considered.","The following exclusion criteria were defined: individuals present in the household who were not part of the household or who refused to give informed consent (IC) (supplement document I), or who had contraindications for the collection of a biological sample, or who had physical and / or health limitations that make it impossible to understand the IC.",All,2020-06-26,2020-07-04,Household and community samples,Multiple groups,5348,0.004,NA,NA,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,"['IgG', 'IgM']",NA,Validated by manufacturers,0.8643,0.9957
Peter Kojo Quashie,Trends of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence in selected regions across Ghana,https://wellcomeopenresearch.org/articles/6-173,No phi_c,Journal Article (Peer-Reviewed),National,Ghana,"Greater Acra Region, Central Region, Eastern Region, Upper East Region","Accra, Kasoa, Cape Coast, Akropong, Navrongo, Bolgatanga","""This study included individuals aged 4 years and above across all study sites.""

""Phase I participants were invited to volunteer for the study at two shopping malls, three major markets/lorry stations (ML1-3), two research institutes involved in COVID-19 work (R1) and COVID-19 testing (RC), and three major hospitals, one of which was a COVID-19 treatment centre (H1, H2, and HC). Phase II screened participants at one market (ML4), one research centre (R1) and two hospitals (H1, H4) while Phase III screened participants at ML1 and across two towns in the Upper East Region (C1). During Phase IV, the exposure levels of upper-income earners were evaluated by screening at 2 malls (M1
and M3) and a repeat screening at H2. In addition, the exposure level in a small town (C3) in the Eastern Region, near Accra, was estimated.""","""Participants with recorded temperature above 37.5°C were excluded.""
""Screening at hospitals and research facilities included only staff members and their close contacts; patients at the hospitals were excluded from this study.""",All,2020-07-27,2020-09-14,Multiple general populations,Multiple groups,1305,0.19,NA,NA,Convenience,UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Wuhan UNscience Biotechnology Co. Ltd,LFIA,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.66,0.94
Saverio Bellizzi,A three-phase population based sero-epidemiological study: Assessing the trend in prevalence of SARS-CoV-2 during COVID-19 pandemic in Jordan,http://dx.doi.org/10.1016/j.onehlt.2021.100292,No phi_c,Journal Article (Peer-Reviewed),National,Jordan,NA,NA,"All persons living in the household were invited to participate in the study, including children to ensure the calculation of age-specific attack rates. Multiple time periods of field visits were conducted to ensure the inclusion of working individuals.","Exclusion criteria included the selection of household with less than 2  members willing to  participate in  the  study, refusal to  provide informed consent and/or contraindication to venipuncture, residential institutions such as boarding schools, dormitories, hostels and prisons were excluded. Suspected, confirmed acute and prior COVID-19 infec-tion were not excluded from participation in the study.",All,2020-08-01,2020-08-31,Household and community samples,Multiple groups,4704,0.003,0.002,0.004,Stratified probability,Wantai SARS-CoV-2 IgM ELISA,Beijing Wantai Biological,ELISA,"['IgG', 'IgM']",NA,NA,NA,NA
Seif Al-Abri,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,https://dx.doi.org/10.1016/j.ijid.2021.09.062,No phi_c,Journal Article (Peer-Reviewed),National,Oman,NA,NA,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",All,2020-07-12,2020-07-23,Household and community samples,Multiple groups,4210,0.055,0.048,0.062,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,IgG,Spike,NA,NA,NA
Alexandra Eriksen,SARS-CoV-2 antibody prevalence among homeless people and shelter workers in Denmark: a nationwide cross-sectional study.,https://dx.doi.org/10.1186/s12889-022-13642-7,No representation,Journal Article (Peer-Reviewed),National,Denmark,NA,NA,PEH (people experiencing homelessness) and shelter workers from 21 assessed sites all over Denmark,NA,All,2020-11-02,2020-11-20,Multiple populations,Multiple groups,819,0.067,NA,NA,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,"['IgG', 'IgM']",NA,Validated by manufacturers,0.9686,0.9939
Anna Popova,Sars-cov-2 seroprevalence structure of the russian population during the covid-19 pandemic,http://dx.doi.org/10.3390/v13081648,No representation,Journal Article (Peer-Reviewed),National,Russian Federation,NA,NA,people across 26 regions of Russia,"active COVID-19 infection at the time of the survey. also, as there could be no more than 30 from one organization, excluded participation in the study by organized groups (preschool institutions, schools, military units, etc.).",All,2020-06-15,2020-12-31,Household and community samples,Multiple groups,74158,0.192,0.189,0.195,Unclear,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,IgG,Nucleocapsid(N-protein),NA,NA,NA
Anna Schaffner,Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study.,https://dx.doi.org/10.3390/jcm9123989,No representation,Journal Article (Peer-Reviewed),National,Liechtenstein,NA,NA,"Contacts of COVID-19 patients that had tested negative by PCR, otherwise no known COVID-19",NA,All,2020-06-02,2020-10-06,Multiple populations,Multiple groups,1159,0.078,0.064,0.095,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Abbott Architect SARS-CoV-2 IgG,LIAISON SARS-CoV-2 S1/S2 IgM,Liaison SARS-CoV-2 S1/S2 IgG,Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit,SGTi-flex COVID-19 IgM/IgG (manual)","Roche Diagnostics,Abbott Laboratories,DiaSorin,EUROIMMUN,Epitope Diagnostics, Inc.,Sugentech, Inc.",Multiple Types,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,NA,NA
Diana Lopez-Farfan,Prevalence of SARS-CoV-2 and co-infection with malaria during the first wave of the pandemic (the Burkina Faso case).,https://dx.doi.org/10.3389/fpubh.2022.1048404,No representation,Journal Article (Peer-Reviewed),National,Burkina Faso,NA,NA,The study was conducted in 11 villages from diﬀerent rural and urban areas in the south of Burkina Faso,NA,All,2020-08-22,2020-11-19,Household and community samples,Multiple groups,998,0.032,0.021,0.043,Unclear,INgezim COVID 19 DR,Eurofins Ingenasa,LFIA,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.945,0.993
Fernando C Barros,COVID-19 and social distancing among children and adolescents in Brazil.,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225319/,No representation,Journal Article (Peer-Reviewed),National,Brazil,NA,NA,general population,NA,All,2020-05-14,2020-06-23,Household and community samples,Multiple groups,89362,0.023,NA,NA,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,NA,NA,Validated by independent authors/third party/non-developers,0.848,0.99
Finnish institute for health and welfare,THL serological population study of the coronavirus epidemic,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,No representation,Institutional Report,National,Finland,NA,NA,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",All,2020-04-19,2020-04-25,Household and community samples,Adults (18-64 years),674,0.003,0.0008,0.0108,Simplified probability,"Author designed (Neutralization Assay),Author designed (IFA) - MULTIPLEXED",NA,Multiple Types,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,NA,NA
Hannah E Clapham,Contrasting SARS-CoV-2 epidemics in Singapore: Cohort studies in migrant workers and the general population,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3826194,No representation,Preprint,National,Singapore,NA,NA,Individuals taking part in the Singapore Population Health Studies  were eligible to take part in this study if they were Singapore Citizens or Permanent Residents aged >=21 years and had a stored serum sample collected prior to between January and August 2019 available for serological testing.,NA,All,2020-11-15,2020-12-15,Household and community samples,Multiple groups,937,0.0016,0.00008,0.0072,Convenience,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,GenScript,Neutralization,Neutralizing,NA,Validated by independent authors/third party/non-developers,0.803,0.993
Heather Kalish,Undiagnosed sars-cov-2 seropositivity during the first 6 months of the covid-19 pandemic in the united states,http://dx.doi.org/10.1126/scitranslmed.abh3826,No representation,Journal Article (Peer-Reviewed),National,US,NA,NA,"This study was designed to determine the seroprevalence of anti–
SARS-CoV-2 antibodies in adults 18 years of age or older in the 
United States who had not been previously diagnosed with COVID-19.",NA,All,2020-04-01,2020-08-04,Household and community samples,Multiple groups,8058,0.046,0.026,0.065,Stratified non-probability,Author designed (ELISA) -Spike,NA,ELISA,"['IgG', 'IgM']",Spike,Validated by developers,NA,NA
Hector Gallardo-Rinco,MIDO COVID: A digital public health strategy designed to tackle chronic disease and the COVID-19 pandemic in Mexico,https://dx.doi.org/10.1371/journal.pone.0277014,No representation,Journal Article (Peer-Reviewed),National,Mexico,NA,NA,"""The study population comprised 58,277 workers of the Carso Group, ... MIDO COVID screening was applied to all asymptomatic individu- als in the workplace and non-pregnant women (pregnant women received normal standard of care as usual).""",NA,All,2020-06-26,2020-12-16,Household and community samples,Adults (18-64 years),58277,0.041,NA,NA,Convenience,Not reported/ Unable to specify,NA,NA,"['IgG', 'IgM']",NA,NA,NA,NA
I Nazaryan,Serological investigation of covid 19 antibodies in Armenia,http://dx.doi.org/10.1515/cclm-2021-5027,No representation,Presentation or Conference,National,Armenia,NA,NA,The cross-sectional study with convenience sampling of individuals who turned to “EcoSense” laboratories to be testedfor COVID 19 IgG were examined.,NA,All,2020-03-15,2020-12-15,Household and community samples,Multiple groups,837,0.2533,NA,NA,Self-referral,NovaLisa® SARS-CoV-2 IgG/IgM,NovaTec Immundiagnostics GmbH,ELISA,IgG,NA,NA,NA,NA
Joe Alex Theu,"SARS-CoV-2 Prevalence in Malawi Based on Data from Survey of Communities and Health Workers in 5 High-Burden Districts, October 2020",https://dx.doi.org/10.3201/eid2813.212348,No representation,Journal Article (Peer-Reviewed),National,Malawi,NA,NA,Survey of Communities and Health Workers,NA,All,2020-10-14,2020-12-08,Household and community samples,Multiple groups,4261,0.078,0.063,0.096,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,TotalAntibody,Spike,Validated by manufacturers,0.967,0.975
Jonathan Silverberg,Predictors of chronic COVID-19 symptoms in a community-based cohort of adults.,https://dx.doi.org/10.1371/journal.pone.0271310,No representation,Journal Article (Peer-Reviewed),National,US,NA,NA,"""Study inclusion criteria included age>18 years, male or female, ability to sign informed consent and for those participating in the synchronous antibody testing drive the release of antibody data to the study investigator.""","""Exclusion criteria were those who were not able to complete the survey or did not agree to release their antibody data to the investigators.""",All,2020-05-13,2020-07-06,Household and community samples,Multiple groups,6665,0.347,NA,NA,Convenience,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,"Epitope Diagnostics, Inc.",ELISA,IgG,Nucleocapsid(N-protein),NA,NA,NA
Maria Skaalum Petersen,"Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.",https://dx.doi.org/10.3201/eid2801.210917,No representation,Journal Article (Peer-Reviewed),National,Faroe Islands,NA,NA,NA,Previous positive reverse transcription PCR (RT-PCR) result. Also excluded 2 newborns,All,2020-11-21,2020-11-30,Household and community samples,Multiple groups,960,0.004,0.001,0.01,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,TotalAntibody,NA,Validated by manufacturers,0.944,1
Mohamed Syed,Antibody Response to SARS-CoV-2: A Cohort Study in Qatar's Primary Care Settings,https://journals.sagepub.com/doi/full/10.1177/21501327211050569,No representation,Journal Article (Peer-Reviewed),National,Qatar,NA,NA,Individuals registered with a mobile number on PHCC electronic medical records and aged ≥10 years were eligible for inclusion.,"Individuals with difficulties related to mobility and communication, bleeding disorders, and mental disabilities were excluded.",All,2020-07-01,2020-07-31,Household and community samples,Multiple groups,943,0.12,NA,NA,Stratified probability,Mindray CL-900i anti-SARS-CoV-2 IgG/IgM,Shenzhen Mindray Bio-Medical Electronics Co.,CLIA,IgG,NA,NA,NA,NA
Mokhtar R Gomaa,"Incidence, household transmission, and neutralizing antibody seroprevalence of Coronavirus Disease 2019 in Egypt: Results of a community-based cohort.",https://dx.doi.org/10.1371/journal.ppat.1009413,No representation,Journal Article (Peer-Reviewed),National,Egypt,"Sharkiyah Governorate, Gharbiyah Governorate, Kafr El Sheikh Governorate, Qalyubiyah Governorate, Fayyoum Governorate",NA,"households raising backyard poultry were selected from five villages in four Nile Delta governorates (Sharkiyah, Gharbiyah, Kafr El Sheikh, and Qalyubiyah) and Fayyoum governorate starting August 2015. All individuals within the household who were older than two years were invited to participate.
The study protocol was amended in April 2020, to allow COVID-19 incidence and seroprevalence studies in four study sites (Fayyoum, Gharbiyah, Kafr El Sheikh, and Qalyubiyah) comprising 290 households.

This cohort was initially intended to study the household transmission of zoonotic influenza viruses in a cohort of Egyptian poultry growers.",NA,All,2020-07-01,2020-07-31,Household and community samples,Multiple groups,1244,0.2,NA,NA,Simplified probability,Author designed (ELISA) -Spike,NA,Neutralization,Neutralizing,NA,NA,NA,NA
Moza Alishaq,Prevalence and risk factors for SARS-CoV-2 infection and seroprevalence among clinical and non-clinical staff in a national healthcare system,http://dx.doi.org/10.1371/journal.pone.0257845,No representation,Journal Article (Peer-Reviewed),National,Qatar,NA,NA,Serum antibody testing for SARS-CoV-2 antibodies was performed on those who requested it or were referred by their clinical care provider.,NA,All,2020-03-01,2020-10-31,Multiple populations,Multiple groups,12126,0.177,NA,NA,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,NA,NA,NA,NA,NA
Nathanael Lapidus,Do not neglect SARS-CoV-2 hospitalization and fatality risks in the middle-aged adult population,https://dx.doi.org/10.1016/j.idnow.2020.12.007,No representation,Journal Article (Peer-Reviewed),National,France,Île-de-France and Grand Est,NA,Data from a seroprevalence study performed in May-June 2020 in 20-to 90-year old subjects were used. This study included sub- jects from three pre-existing general adult population cohorts from Île-de-France (N = 6348) and Grand Est (N = 3434),NA,All,2020-05-15,2020-06-15,Household and community samples,Multiple groups,9782,0.0346,NA,NA,Simplified probability,"Anti-SARS-CoV-2 NCP ELISA (IgG),Anti-SARS-CoV-2 ELISA IgG,Author designed (Neutralization Assay)","EUROIMMUN,NA",Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",NA,NA,NA
Nazila Hajiahmadi,SARS-CoV-2 seroprevalence in asymptomatic or mild symptomatic people and symptomatic patients with negative PCR results: The hidden perspective in epidemiological reports,10.1101/2021.07.11.21260336,No representation,Preprint,National,Iran,NA,"Tehran, Mashhad","Only extracting group 1:
""peripheral venous blood samples were collected from two groups of people from Tehran and Mashhad cities: (1) asymptomatic, mildly symptomatic, or symptomatic volunteer participants who have not referred to medical centers due to COVID-19 symptoms and (2) severe symptomatic hospitalized patients with negative PCR results.""","""Symptomatic volunteers at sampling time were excluded from volunteer group.""",All,2020-05-30,2020-06-17,Multiple populations,Multiple groups,716,0.173,0.088,0.258,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.941,0.983
Olivier Robineau,Long-lasting Symptoms After an Acute COVID-19 Infection and Factors Associated With Their Resolution.,https://dx.doi.org/10.1001/jamanetworkopen.2022.40985,No representation,Journal Article (Peer-Reviewed),National,France,NA,NA,"""This cross-sectional study is part of the SAPRIS-SERO (Santé, Pratiques, Relations et Inégalités Sociales en Population Générale Pendant la Crise COVID-19–Sérologie) survey"".

""In brief, data from 3 general, adult population–based French cohorts (E3N/E4N, CONSTANCES [Consultants des Centres d’Examens de Santé], and Nutrinet-Santé) were included in this study.""

""Only participants with internet access were invited to participate in the present study.""

""Only individuals who participated in the first 2 waves of SAPRIS-SERO questionnaires, the serologic survey, and the follow-up questionnaire were included in the analysis.""",NA,All,2020-05-01,2020-11-30,Household and community samples,Multiple groups,53047,0.0168,NA,NA,Unclear,"Anti-SARS-CoV-2 ELISA IgG,Author designed (Neutralization Assay)","EUROIMMUN,NA",Multiple Types,"['IgG', 'Neutralizing']",Spike,NA,NA,NA
Pavel Piler,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,https://doi.org/10.1038/s43856-022-00080-0,No representation,Journal Article (Peer-Reviewed),National,Czechia,NA,NA,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,All,2020-10-01,2020-11-30,Household and community samples,Multiple groups,3626,0.279,0.261,0.297,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant","DiaSorin,Abbott Laboratories",CLIA,IgG,Spike,NA,NA,NA
Robert Stout,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,No representation,Journal Article (Peer-Reviewed),National,US,NA,NA,Well life insurance applicants in Sept 2020,NA,All,2020-09-01,2020-09-30,Household and community samples,Multiple groups,61910,0.066,NA,NA,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998
Rosemary Audu,Seroprevalence of SARS-CoV-2 in four states of Nigeria in October 2020: A population-based household survey.,https://dx.doi.org/10.1371/journal.pgph.0000363,No representation,Journal Article (Peer-Reviewed),National,Nigeria,"Enugu, Gombe, Nasarawa, Lago",NA,Households - all individuals in household were eligible,NA,All,2020-10-01,2020-10-31,Household and community samples,Multiple groups,10628,0.182,NA,NA,Convenience,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 NCP ELISA (IgG),xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay","Abbott Laboratories,EUROIMMUN,Luminex Corporation",Multiple Types,IgG,"['Nucleocapsid (N-protein)', 'Spike, Nucleocapsid (N-protein)']",NA,NA,NA
Sarah Lofgren,Feasibility of SARS-CoV-2 Antibody Testing in Remote Outpatient Trials,https://academic.oup.com/ofid/article/8/11/ofab506/6382457?login=true,No representation,Journal Article (Peer-Reviewed),National,US,NA,NA,"""Inclusion criteria for the postexposure prophylaxis trial required persons to have a known exposure (within the previous 4 days) to a lab-confirmed SARS-CoV-2 case either as a health care worker, a first responder, or a household contact. Individuals were enrolled into the preemptive early treatment trial with COVID-19 symptoms (≤4 days duration) and either
lab-confirmed SARS-CoV-2 or high-risk exposure to a known case within 14 days of symptom onset. The pre-exposure prophylaxis trial inclusion criteria required persons to be high-risk health care workers or first responders with ongoing occupational exposure to COVID-19 patients.""

""While overall trial participation included persons living in the United States or select Canadian provinces, only participants in the United States were eligible for participation in the serology substudy.""

""Full details regarding inclusion and exclusion criteria have been published elsewhere [10-12]"".","""Full details regarding inclusion and exclusion criteria have been published elsewhere [10-12]"".",All,2020-04-06,2020-07-13,Multiple populations,Multiple groups,542,0.04,NA,NA,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,IgG,Spike,NA,NA,NA
Shamez Ladhani,"Prospective Active National Surveillance of Preschools and Primary Schools for SARS-CoV-2 Infection and Transmission in England, June 2020",https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3764198,No representation,Preprint,National,UK,England,NA,"For the blood sampling arm, schools were approached in five regions where a paediatric investigation team could be assembled: North London, East London, Oxford, Derby and Manchester. Headteachers in participating schools sent the study information pack to staff and parents and asked them to return a signed consent form with a completed questionnaire before the sampling day.",NA,All,2020-06-01,2020-06-15,Multiple populations,Multiple groups,2198,0.136,0.124,0.151,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,IgG,Nucleocapsid(N-protein),NA,NA,NA
Tanawin Nopsopon,COVID-19 seroprevalence among hospital staff and preprocedural patients in Thai community hospitals: a cross-sectional study.,https://dx.doi.org/10.1136/bmjopen-2020-046676,No representation,Journal Article (Peer-Reviewed),National,Thailand,"Northern Region, Northeastern Region, Central Region, Eastern Region, Southern Region",NA,"From 8 April to 26 June 2020, hospital staff and patients who needed procedural treatment or operation visiting the hospital during the recruiting period and did not meet the national nasopharyngeal PCR testing criteria in 244 hospitals (215 community hospitals and 29 general hospitals) from all regions of Thailand were recruited for antibody testing in their community hospital. Hospitals included in the study came from a national survey about willingness to use antibody testing for COVID-19 screening.",Participants with active symptoms meeting national criteria for nasopharyngeal PCR testing were quarantined and excluded.,All,2020-04-06,2020-06-26,Multiple populations,Adults (18-64 years),857,0.063,NA,NA,Convenience,Baiya Rapid COVID-19 IgG/IgM Test Kit,Baiya Phytopharm,LFIA,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.941,0.98
Tasnim Hasan,Sero-prevalence of sars-cov-2 antibodies in high-risk populations in vietnam,http://dx.doi.org/10.3390/ijerph18126353,No representation,Journal Article (Peer-Reviewed),National,Viet Nam,"Hanoi Capital, Quang Nam Province, Da Nang Province","Hoi sub-commune in Ha Loi commune, Me Linh district, Hanoi Capital,  Giao Ai sub-commune in Dien Hong commune, Dien Ban, Quang Nam Province, Luu Minh sub-commune in Ha Lam Town, Quang Nam, Le Son Nam sub-commune in Hoa Tien commune, Da Nang","All people residing in each sub-commune during the outbreaks who were aged 5 years and
older and who were capable of giving consent, or having consent given by a guardian (for
children <16 years), were eligible to participate.
Enrolled participants
were classified as close contacts, household contacts, or general community members.
Close contacts of COVID-19 cases were those who been within a two-meter distance of the
COVID-19 case for at least 15 min, or had been present in the same room for at least two
hours during the infectious period (that is, from 48 h prior to symptom onset or diagnosis
until the person with confirmed COVID-19 was placed in isolation). Household contacts of
a COVID-19 case were those who were not close contacts, but who were living in the same
dwelling and sharing meals or the kitchen with a COVID-19 case during the infectious
period. General community members were those who were not close or household contacts
of the COVID-19 case, but were living in the same sub-commune as the COVID-19 case.
","Individuals were excluded if they were unable or refused to provide consent, were less than
five years of age or if they were a household/community member who had not stayed in the
same house/sub-commune during the infectious period. Individuals who were documented as
PCR-positive for COVID-19 during the outbreaks were excluded from testing",All,2020-09-04,2020-11-23,Household and community samples,Multiple groups,3034,0.004,NA,NA,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,IgG,NA,Validated by independent authors/third party/non-developers,0.968,0.998
Wajiha Javed,Seroprevalence and characteristics of Coronavirus Disease (COVID-19) in workers with non-specific disease symptoms,https://doi.org/10.1186/s12879-022-07461-9,No representation,Journal Article (Peer-Reviewed),National,Pakistan,Sindh; Punjab; Khyber Pakhtunkhwa; Balochistan.,Karachi; Lahore; Multan; Peshawar; and Quetta.,"""Participants between 18 to 65 years of age were recruited during April-September 2020 from the workplaces, including factories, corporates, restaurants, media houses, schools, banks, and hospitals, located in Karachi, Lahore, Multan, Peshawar, and Quetta"".","""non-consenting individuals, PCR-positive at the time of screening, having past 14-days history of COVID-19 and COVID-19 vaccine trials’ participants were excluded.""",All,2020-04-15,2020-09-15,Multiple populations,Adults (18-64 years),17764,0.1582,NA,NA,Convenience,IgG/IgM Test Kit (Colloidal gold),Getz Pharma,LFIA,"['IgG', 'IgM']",NA,NA,NA,NA
Zacharoula Bogogiannidou,"Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020.",https://dx.doi.org/10.3390/vaccines9050504,No representation,Journal Article (Peer-Reviewed),National,Greece,NA,NA,"The leftover serum samples were collected from a nationwide laboratory network, including both private microbiological laboratories as well as microbiological and biochemical laboratories of public hospitals. A total of 36 laboratories participated. The samples were derived from individuals who visited the laboratories for routine screening and reasons unrelated to COVID-19.","Our positive results reflect mainly mild or asymptomatic cases, since confirmed COVID-19 cases that occurred during the same month were excluded from the sampling framework.",All,2020-05-01,2020-08-31,Household and community samples,Multiple groups,20110,0.0019,0.0008,0.003,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,0.997
Chantal Snoeck,Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study.,https://www.medrxiv.org/content/10.1101/2020.05.11.20092916v1,Preprint,Preprint,National,Luxembourg,NA,NA,Resident of Luxembourg,"Infection by Coronavirus with severe disease course requiring a hospital admission prior to the inclusion to the study, presence of fever and respiratory distress/cough at the time of inclusion not attributable to other known chronic disease, age > 79 years, individuals living across the borders",All,2020-04-15,2020-05-05,Household and community samples,Multiple groups,1820,0.0209,0.0137,0.0282,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,IgG,NA,Validated by independent authors/third party/non-developers,0.857,0.978
Fabrice Carrat,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",https://dx.doi.org/10.1007/s15010-021-01731-5,Better study available,Journal Article (Peer-Reviewed),National,France,"Haut de France, Normandi, Ile de France, Bretagne, Grand Est, Bourgogne France Comte, Centre val de Loire, Auvergne Rhome Alpes, Pays de Loire, Occitanie, Nouvelle Aquitaine, Provence-Alpes-Côte d'Azur",NA,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",NA,All,2020-05-04,2020-09-30,Household and community samples,Multiple groups,82126,0.051,0.049,0.054,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975
Harvey W Kaufman,"Insights from Patterns of SARS-CoV-2 Immunoglobulin G Serology Test Results from a National Clinical Laboratory, United States, March-July 2020",http://dx.doi.org/10.1089/pop.2020.0256,No asymptomatics,Journal Article (Peer-Reviewed),National,US,NA,NA,"Results from SARS-CoV-2 NAAT and qualitative IgG tests performed at Quest Diagnostics through July 10, 2020, were included in the analysis.","Results were excluded for pa-
tients who were <2 years of age at the time of testing",All,2020-04-21,2020-07-10,Household and community samples,Multiple groups,2402282,0.1181,NA,NA,Sequential,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,EUROIMMUN",Multiple Types,IgG,NA,NA,NA,NA
Kamille Fogh,Testing Denmark: A Danish nationwide surveillance study of COVID-19,https://journals.asm.org/doi/10.1128/spectrum.01330-21,No asymptomatics,Journal Article (Peer-Reviewed),National,Denmark,NA,NA,"1.3 million Danish citizens >15 years (22% of the population) were randomly drawn from the Civil Registration System and invited to participate via the governmental, personal, password protected digital mailbox system (e-Boks) from September 25, 2020.",NA,All,2020-10-02,2020-10-11,Household and community samples,Multiple groups,318552,0.0079,NA,NA,Simplified probability,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.933,0.982
Mohammad Talaei,Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK).,https://dx.doi.org/10.1186/s12916-022-02286-4,Better study available,Journal Article (Peer-Reviewed),National,UK,"England, Scotland, Wales, and Northern Ireland",NA,"This antibody study is an add-on study to the COVIDENCE UK study - COVIDENCE UK is a prospective, longitudinal, population-based observational study of COVID-19 in the UK population (www.qmul.ac.uk/covidence). Inclusion criteria for COVIDENCE UK were age 16 years or older and UK residence at enrolment. COVIDENCE UK launched on May 1, 2020.

Antibody study included included all participants who enrolled in the study between May 1 and November 2, 2020, partaking in serology testing who were not vaccinated against COVID-19 or who provided their dried blood spot sample on or before the date of their first COVID-19 vaccination.",No exclusion criteria for COVIDENCE UK cohort.,All,2020-05-01,2020-11-02,Household and community samples,Multiple groups,11130,0.152,NA,NA,Self-referral,Human Anti-IgG/A/M SARS-CoV-2 ELISA,The Binding Site,ELISA,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.986,0.983
Naif Khalaf Alharbi,Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia,https://doi.org/10.1016/j.jiph.2021.04.006,No representation,Journal Article (Peer-Reviewed),National,Saudi Arabia,"Riyadh, Jazan, Qassim, Hail, Al-Ahsa, Makkah",NA,"11,272 samples were collected from six provinces of KSA; 5395 samples were collected from the blood donors and 5877 samples from the non-COVID-19 patients. The non- COVID-19 patients were defined as any person who is visiting a clinic or admitted at a hospital with samples collected for clinical biochemistry blood testing and confirmed to be negative for COVID-19 by RT-PCR.",NA,All,2020-06-15,2020-11-15,Multiple general populations,Multiple groups,11275,0.109,0.103,0.116,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (ELISA) -Spike","EUROIMMUN,NA",ELISA,IgG,Spike,NA,NA,NA
